EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)

Maarten A Hanrath, Evi Banken, Sebastian A H van den Wildenberg, Daan van de Kerkhof, Dirk Jan A R Moes, Michele Boisdron-Celle, Bianca J C van den Bosch, Ramon Bax, Pierre M Bet, Jan Gerard Maring, Geert-Jan M Creemers, Irene E G van Hellemond und 1 weitere

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04759-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Maarten A Hanrath und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands. Hauptthemen laut MEDLINE: Fluorouracil, Thymine, Gastrointestinal Neoplasms, Antimetabolites, Antineoplastic. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In 20–30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. Therefore, DPYD genotyping became standard practice before treatment with fluoropyrimidines. Nevertheless, only 17% of the patients with severe toxicity have a DPYD variant. Therefore, an urgent need persists to investigate other strategies contributing to prediction and prevention of toxicity. Endogenous DPD substrates are considered as potential biomarkers to predict toxicity, yet contradictional data exist on demonstrating uracil as a reliable biomarker. Thymine as biomarker for toxicity has been investigated less. The aim of this study was to determine the association between the concentrations of uracil, thymine dihydrouracil (DHU) and dihydrothymine (DHT), with the systemic drug exposure of 5-FU and DPD enzyme activity in patients treated with 5-FU.

Methods

We included 36 patients with gastrointestinal malignancy who received 5-FU infusion. DPYD genotyping was conducted before start of treatment. Blood samples for determining 5-FU, uracil and thymine concentrations during infusion and DPD enzyme activity were taken.

Results

We found a significant correlation between the 5-FU systematic exposure and baseline thymine concentrations ( R 2 = 0.1468; p = 0.0402). DPD enzyme activity was significantly correlated with baseline thymine concentrations but no correlation was found between DPD enzyme activity and 5-FU systemic drug exposure.

Conclusion

5-FU dose individualization based on thymine concentrations could be a promising addition to DPYD genotyping to predict 5-FU-induced toxicity. Larger prospective trials are needed to examine thymine as predictor for toxicity in daily practice.

Trial registration

Trial NL7539 at ‘Overview of Medical Research in the Netherlands’ (ID NL-OMON21471). Date of registration 19-02-2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorouracilThymineGastrointestinal NeoplasmsAntimetabolites, AntineoplasticHumansMaleFemaleMiddle AgedProspective StudiesAgedDihydrouracil Dehydrogenase (NADP)UracilAdultBiomarkers, TumorBiomarkersAged, 80 and overGenotype

Stichwörter der Autor:innen

5-FlurouracilEndogenous DPD substratesGastrointestinal cancerThymineToxicity

Substanzen

FluorouracilThymineDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticUracildihydrouracilBiomarkers, TumorBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.
  • Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Department of Clinical Chemistry, Catharina Hospital, Eindhoven, the Netherlands.
  • Laboratory of Chemical Biology, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.

Zitieren

APA

Hanrath, M. A., Banken, E., van den Wildenberg, S. A. H., van de Kerkhof, D., Moes, D. J. A. R., Boisdron-Celle, M., van den Bosch, B. J. C., Bax, R., Bet, P. M., Maring, J. G., Creemers, G. M., van Hellemond, I. E. G., & Deenen, M. J. (2025). Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial). Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04759-8

Vancouver

Hanrath MA, Banken E, van den Wildenberg SAH, van de Kerkhof D, Moes DJAR, Boisdron-Celle M, et al. Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial). Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04759-8

BibTeX
@article{Hanrath2025,
  author = {Hanrath, Maarten A and Banken, Evi and van den Wildenberg, Sebastian A H and van de Kerkhof, Daan and Moes, Dirk Jan A R and Boisdron-Celle, Michele and van den Bosch, Bianca J C and Bax, Ramon and Bet, Pierre M and Maring, Jan Gerard and Creemers, Geert-Jan M and van Hellemond, Irene E G and Deenen, Maarten J},
  title = {Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04759-8}
}
Kostenlos starten →